UNSPSC 51343808: Elvitegravir/cobicistat/emtricitabine/tenofovir

A multi-drug combination indicated as a complete regimen for the treatment of HIV-1.

UNSPSC 51343808 Elvitegravir/cobicistat/emtricitabine/tenofovir is a Commodity code that encompasses pharmaceutical products for HIV treatment and related antiretroviral therapies. Recent state and local opportunities under this code show purchasing activity driven by public health departments and counties acquiring pharmaceutical inventory through cooperative purchasing vehicles and competitive bidding processes, though the recent record includes both on-code pharmaceutical procurements and off-code health-supply acquisitions tagged under the same UNSPSC classification. State and local issuing bodies soliciting in this space include state departments of public health and county health authorities, typically using piggyback cooperative contracts and invitations for bid to secure inventory at scale with multi-year terms and renewal options.

Activity appears concentrated in the Great Lakes and Southeast regions. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 via IFB process for antibiotic and antimicrobial products with 12-month initial terms and two renewal options. Seminole County, Florida issued an IFB on June 30, 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, a two-year initial term, and a one-year renewal option—a procurement positioned outside the antiretroviral scope but tagged to this code. Cooperative purchasing vehicles such as MMCAP Infuse and county e-procurement portals remain the primary procurement pathways, with contracts typically structured around annual volumes, fixed-fee pricing, quarterly or periodic delivery cycles, and standard compliance requirements including drug-free workplace certification and E-Verify.